a number of oncogenic proteins and receptors (eg, p53, c-Myc, Akt, cyclin D, Cdk4, ALK) that are deregulated in lymphoma, preventing their degradation (see figure) . Overexpression of HSPs has been documented in different lymphoma subtypes and it contributes to the oncogenic process. 3 Inhibition of HSPs that specifically bind to proteins involved in lymphomagenesis may be of great value for the treatment of these diseases. The authors show that HSPH1, a subgroup of the HSP70 family of proteins, is expressed in B-cell lymphomas, preferentially in those with a high proliferation rate. HSPH1 protein expression directly correlates with BCL-6 and c-Myc protein expression in aggressive lymphoma cell lines. In fact, the authors convincingly show that HSPH1 directly binds to BCL-6 and c-Myc, thus acting as a chaperone for these proteins. Most important, in a series of in vitro studies, the authors show that HSPH1 inhibition directly downregulates BCL-6 and c-Myc, which leads to a significant decrease in cell proliferation. To further evaluate this concept, the group tested the growth of an aggressive B-cell lymphoma line in an in vivo model. Mice transplanted with HSPH1-knocked-down tumors had significantly longer survival, and the protein levels of BCL-6 and c-Myc in the tumor cells were decreased, in agreement with the reported in vitro studies. In addition, tumor angiogenesis was also reduced, consistent with the inhibition of the provascularization properties of c-Myc, which may additionally contribute to the antitumoral effect.
Finally, to enhance the clinical relevance of this finding, the investigators analyzed the expression of HSPH1 in primary B-cell lymphomas. In a previous study, they showed that HSPH1 protein expression was correlated with the tumor proliferation rate. Thus, low-grade lymphomas showed a significantly lower HSPH1 tumor expression than high-grade lymphomas. 4 In particular, diffuse large B-cell lymphoma (DLBCL) with a high Ki-67 index and Burkitt lymphoma appear to have higher HSPH1 expression. In line with these data, HSPH1 protein expression in a transformed DLBCL was significantly increased compared with the expression seen in the indolent lymphoma. Remarkably, in c-Myc 1 lymphomas, HSPH1
protein expression correlated with that of c-Myc.
Overall, these data suggest that HSPH1 inhibition could potentially be useful in those lymphomas with c-Myc alterations (ie, Burkitt and the so-called "double-hit" lymphomas-mature B-cell lymphomas with a translocation affecting c-Myc in combination with another translocation usually affecting bcl-2). This is of paramount relevance, in particular for the latter, amounting to a poor-prognosis lymphoma for which no effective therapies have been developed so far. 5 A few studies have addressed the inhibition of other HSPs as a treatment of B-cell lymphoma. In particular, HSP90, an important chaperone involved in cancer, 6 is frequently expressed in DLBCL and, importantly, its expression highly correlates with BCL-6, 7 Pharmacologic inhibitors of HSPH1 have yet to be developed, but the discovery of HSPH1 as a chaperone of c-Myc in B-cell lymphoma presents an important opportunity to design rational, molecularly based treatments for c-Myc-dependent B-cell lymphomas such as Burkitt lymphoma and the "double-hit" DLBCL.
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I
t is increasingly the case that a deeper knowledge of the crosstalk between leukemic stem and progenitor cells and their bone marrow microenvironment is needed to fully understand how the latter influences leukemia development, progression, and resistance to targeted therapies. This also appears to be true for those cases of CML that show BCR-ABL1 kinase-independent resistance to TKI therapy.
Given that missense mutations in the BCR-ABL1 kinase domain explain only 30% to 40% of clinical imatinib resistance cases, and that ;20% to 40% of newly diagnosed CML patients eventually require alternative therapies due to TKI intolerance or resistance, 2 the understanding of the still largely unclear molecular events regulating drug resistance in patients without BCR-ABL1 mutations appears to be of extreme clinical relevance. As also indicated by Khorashad et Genes with a potential role in resistance were selected based on criteria designed to minimize false-positive results. The RAS-related nuclear protein RAN and the karyopherin b family member XPO1 (exportin-1, also called chromosome maintenance protein 1 [CRM1]), two interacting proteins with key functions in nucleocytoplasmic transport, were among the top 5 candidates, suggesting a role for these factors and corresponding signal transduction pathways in BCR-ABL1-independent TKI resistance (see figure) . RAN is involved in the transport of proteins across the nuclear envelope by interacting with karyopherins and changing their ability to bind or release cargo molecules. Cargo proteins containing nuclear localization signals are bound by importins and transported into the nucleus. Inside the nucleus, RAN-guanosine triphosphate (GTP) binds to importin and releases the import cargo. Cargo that needs to exit the nucleus into the cytoplasm binds to exportin in a ternary complex with RAN-GTP. Interestingly, Khorashad et al 1 also
identified through the shRNA library screen many other pathways whose roles in TKI resistance are yet to be experimentally validated. Among these pathways are genes involved in proteasomal protein degradation, chromatin remodeling, protein biosynthesis, cell-cycle regulation, apoptosis, antioxidation, ubiquitination, and DNA repair.
In particular, 5 of the top 50 genes (PSMA1, UBE1, NEDD8, PSMD3, and PSMD1) are associated with proteasome-dependent protein degradation, which has been implicated in TKI resistance of leukemic stem and progenitor cells. 6 Thus, nuclear export and signaling linking the stem/progenitor cell to the microenvironment will further elucidate BCR-ABL-independent signaling in CML and AML. XPO1/RAN-mediated export was implicated in many types of solid tumors and hematologic malignancies. [7] [8] [9] [10] Given that XPO1 is a critical regulator of cell proliferation and survival, which is not only overexpressed but also described as a poor prognostic factor in different hematologic malignancies, it is not surprising that different inhibitors of XPO1-mediated export through the nuclear pore complex have been developed. Among these, the selective inhibitors of nuclear export (SINE; Karyopharm Therapeutics) are leptomycin B-based small molecules that irreversibly bind to Cys528 in the cargo-binding groove of XPO1 to prevent
Mechanisms of oncogene kinase-independent resistance to TKI therapy in CML with wild-type BCR-ABL1 and FLT3-ITD 1 AML. The expression of the nuclear export factors RAN and XPO1 was found to be increased in CML and AML in an oncogene kinase-independent manner and likely through either signals generated by the microenvironment or by cell-autonomous BCR-ABL or FLT3-ITD kinase-independent signals (A). This results in increased nuclear export of their cargo that also is comprehensive of oncogenic signal transducers (eg, SET) and tumor-suppressor proteins (eg, p53) that if delocalized become activated and inactivated, respectively. Such an effect together with the BCR-ABL1-or FLT3-ITD-generated oncogenic signals will both enhance proliferation and/or survival of myeloid progenitors. Interestingly, Khorashad et al 1 show that the activity of XOP1 and RAN seems to specifically control those oncogene kinase-independent molecular events leading to resistance to TKI-induces apoptosis. Khorashad et al 1 reported that inhibition of nuclear export by downregulation of RAN or pharmacologic inhibition of XPO1 activity by the clinically relevant karyopherin inhibitor KPT-330 results in nuclear accumulation of their cargo and, consequently, restored sensitivity of leukemic progenitors to TKI-induced inhibition of proliferation and/or survival and restoration of sensitivity to TKI treatment (B). figure) . The end of the line for neutrophils
XPO1-cargo interactions (see
In this issue of Blood, Bartels and colleagues demonstrate that acetylation of the transcription factor CCAAT enhancer binding protein e (C/EBPe) is essential for terminal neutrophil granulocyte differentiation.
1 N eutrophils, the most abundant granulocytes, are essential for host innate immune defense. Neutropenia results from damage to the bone marrow or depletion or destruction of neutrophils by drugs, diseases, or congenital disorders that block neutrophil differentiation. Neutropenic individuals are extremely susceptible to bacterial infection, and febrile neutropenia increases the risk of mortality in cancer patients receiving myelosuppressive chemotherapy. 2 Prophylactic use of granulocyte colonystimulating factor (G-CSF) reduces mortality by increasing neutrophil numbers. 2 A better understanding of the mechanisms that regulate granulopoiesis and terminal neutrophil differentiation could spur development of new strategies to overcome neutropenia and improve clinical outcomes. The C/EBP transcription factor family is essential for granulopoiesis and terminal differentiation of neutrophils.
3 C/EBPa is predominantly expressed in immature myeloid cells, and lack of expression leads to a block at the myeloblast stage. 3 C/EBPb is expressed from the metamyelocyte stage and on during maturation. 3 C/EBPb-deficient mice display normal granulocyte differentiation and steadystate levels of neutrophils but are unable to produce neutrophils in response to cytokine
Acetylation of C/EBPe is essential for terminal neutrophil differentiation and function. C/EBPe is acetylated during granulocytic differentiation toward neutrophils by lysine acetylases (KAC, eg, p300) or lysine deacetylase inhibitors (KDACi, eg, nicotinamide inhibiting KDAC SIRT1). Acetylation on K121 and K198 is essential for terminal differentiation of neutrophils and expression of secondary granule proteins. Differential acetylation of C/EBPe could be important for determining differentiation along the neutrophil or eosinophil lineages.
